Clinical Trial – SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma – Hodgkin Lymphoma

Chinese PLA General Hospital is running a clinical trial to test drugs called SHR-1210 and Decitabine in two separate phases to treat Hodgkin Lymphoma. The purpose of this study is to evaluate whether treatment with the study drug decitabine in combination with SHR-1210 is safe and feasible, is more effective than treatment with SHR-1210 alone,and reverse the resistance of Anti-PD-1 antibody in patients with HL.

The drugs are SHR-1210 and Decitabine.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: PD-1 Blockade With SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma:an Open-label Phase I/II Trial
Actual Study Start Date : September 4, 2017
Estimated Primary Completion Date : August 21, 2018
Estimated Study Completion Date : March 21, 2019

For enrollment please visit www.clinicaltrials.gov.

 

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.